Stocks Health care AMLX
NASDAQ · Health careAmylyx Pharmaceuticals, Inc. (AMLX)
It posted a net loss of $163.2M. In fiscal 2025 capital spending exceeded operating cash flow by $123.5M. At September 30, 2026 it held $240.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Amylyx Pharmaceuticals, Inc.
- Net worth
- Amylyx Pharmaceuticals, Inc. has a market value (market cap) of $3.4B at the latest share price, and shareholders' equity of $753.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0 (-100.0% year on year), with a net loss of $144.7M.
- Cash flow
- In fiscal 2025 operations used $123.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Amylyx Pharmaceuticals, Inc.'s next report is expected around March 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Amylyx Pharmaceuticals, Inc. does
Amylyx Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AMLX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$144.7M | -$1.53 | -$123.5M |
| 2024 | $87.4M | -$301.7M | -$4.43 | -$167.8M |
| 2023 | $380.8M | $49.3M | $0.70 | $10.7M |
| 2022 | $22.2M | -$198.4M | -$3.39 | -$182.4M |
| 2022 | $285K | -$87.9M | -$13.35 | -$75.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Amylyx Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026
- September 8, 2026
- August 20, 2026
- August 18, 2026Other event 8-K
- August 18, 2026
- August 6, 2026
- August 6, 2026
- June 4, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Amylyx Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $3.8M worth of shares in the last 90 days and bought none on the open market. 22% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 5, 2026 | Milne George M JrDirector | Soldpre-planned (10b5-1) | 30,000 | $830.9K |
| September 10, 2026 | Klee Justin B.Co-Chief Executive Officer, Director | Sold | 29,025 | $932.6K |
| September 10, 2026 | Klee Justin B.Co-Chief Executive Officer, Director | Sold | 1,439 | $47.7K |
| September 10, 2026 | Cohen Joshua BCo-Chief Executive Officer, Director | Sold | 29,545 | $950K |
| September 10, 2026 | Cohen Joshua BCo-Chief Executive Officer, Director | Sold | 919 | $30.5K |
| September 10, 2026 | Mazzariello GinaChief Legal Officer | Sold | 9,525 | $309.1K |
| September 10, 2026 | Mazzariello GinaChief Legal Officer | Sold | 11 | $366.7 |
| September 10, 2026 | Frates James MChief Financial Officer | Sold | 9,768 | $315.2K |
Who owns AMLX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 15% | February 5, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 7.5% | May 15, 2026 |
| TCG Crossover GP II, LLC13G, passive with 2 related filers | 5.7% | February 17, 2026 |
| Commodore Capital LP13G, passive with 3 related filers | 5.1% | November 17, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 207 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 16,727,909 | +97,368 |
| BlackRock, Inc. | 8,827,085 | -1,751 |
| Perceptive Advisors LLC | 8,334,882 | +50,000 |
| TCG Crossover Management, LLC | 6,243,812 | 0 |
| Commodore Capital LP | 5,650,000 | 0 |
| Jupiter Topco LLC | 5,236,102 | new |
| Saturn V Capital Management LP | 4,624,101 | +274,216 |
| Vanguard Capital Management LLC | 4,224,224 | +82,649 |
| Morgan Stanley | 3,130,808 | +955,261 |
| Driehaus Capital Management LLC | 3,036,970 | +49,823 |
| First Light Asset Management, LLC | 3,023,256 | -167,389 |
| Franklin Resources Inc | 2,950,225 | +688,656 |
| Goldman Sachs Group Inc | 2,858,239 | +232,248 |
| State Street Corp | 2,603,337 | +240,176 |
| Geode Capital Management, LLC | 2,335,315 | +124,383 |
| Jpmorgan Chase & Co | 1,863,650 | +1,703,987 |
| Adage Capital Partners GP, L.L.C. | 1,900,000 | -1,660,764 |
| Siren, L.L.C. | 1,480,586 | +250,586 |
| Eventide Asset Management, LLC | 1,327,536 | -186,422 |
| 683 Capital Management, LLC | 1,279,512 | -250,488 |
Insiders
7 insiders reported holding 8,828,487 shares in total, about $266.7M at the last price.
| Holder | Shares |
|---|---|
| Cohen Joshua BCo-Chief Executive Officer, Director | 3,613,123 |
| Klee Justin B.Co-Chief Executive Officer, Director | 3,613,056 |
| Milne George M JrDirector | 782,881 |
| Bedrosian Camille LChief Medical Officer | 278,064 |
| Frates James MChief Financial Officer | 233,625 |
| Mazzariello GinaChief Legal Officer | 190,838 |
| Firestone KarenDirector | 116,900 |
Questions about AMLX
What does Amylyx Pharmaceuticals, Inc. do?
Amylyx Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as AMLX. Its shares trade on NASDAQ under the ticker AMLX.
What is Amylyx Pharmaceuticals, Inc.'s net worth?
Amylyx Pharmaceuticals, Inc. has a market value (market cap) of $3.4B at the latest share price, and shareholders' equity of $753.7M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Amylyx Pharmaceuticals, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $163.2M.
When did Amylyx Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the planned insider sale from November 9, 2026.
When is Amylyx Pharmaceuticals, Inc.'s next earnings report?
Amylyx Pharmaceuticals, Inc.'s next report is expected around March 2, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AMLX with
Follow AMLX
Get an email when Amylyx Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Amylyx Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.